Abstract Purpose of Review Although bariatric surgery is the most effective treatment of
severe obesity, a proportion of patients experience clinically significant weight regain (WR) …

Abstract Background This “Anti-Obesity Medications and Investigational Agents: An Obesity
Medicine Association Clinical Practice Statement 2022” is intended to provide clinicians an …

Objective The aim of this study was to compare the effectiveness of semaglutide versus
liraglutide for treating post‐metabolic and bariatric surgery (MBS) weight recurrence …

Abstract Purpose About 20–25% of patients experience weight regain (WR) or insufficient
weight loss (IWL) after bariatric metabolic surgery (BS). Therefore, we aimed to …

Over the past 50 years, many countries around the world have faced an unchecked
pandemic of obesity and type 2 diabetes (T2DM). As best practice treatment of T2DM has …

Abstract Purpose of Review The burden of obesity worldwide is high and projected to rise.
Obesity increases the risk of several cardiovascular diseases and cardiometabolic risk …

While bariatric surgery restults in significant long-term weight loss for most patients with
obesity, post-surgical weight gain affects a considerable percentage of patients to varying …

Summary About 20%–25% of patients experience weight regain (WR) or insufficient weight
loss (IWL) following bariatric surgery (BS). Therefore, we aimed to retrospectively assess the …

The following literature search is in response to inquiries made to the American Society for
Metabolic and Bariatric Surgery (ASMBS) regarding antiobesity medication (AOM) use in …

Background Combination anti‐obesity medications (AOMs) to treat postoperative bariatric
surgery weight regain have limited data on their use in the clinical setting. Understanding …